Personalized medicine and pharmacogenomics – Mayo Clinic

Personalized medicine and pharmacogenomics

Pharmacogenomics holds the promise that drugs might one day be tailored to your genetic makeup.

Modern medications save millions of lives a year. Yet any one medication might not work for you, even if it works for other people. Or it might cause severe side effects for you but not for someone else.

Your age, lifestyle and health all influence your response to medications. But so do your genes. Pharmacogenomics is the study of how a person's unique genetic makeup (genome) influences his or her response to medications.

Pharmacogenomics is part of a field called personalized medicine also called individualized or precision medicine that aims to customize health care, with decisions and treatments tailored to each individual patient in every way possible.

Although genomic testing is still a relatively new development in drug treatment, this field is expanding. Currently, more than 100 drugs have label information regarding pharmacogenomic biomarkers some measurable or identifiable segment of genetic information that can be used to direct the use of a drug.

Each gene provides the blueprint for the production of a certain protein in the body. A particular protein may have an important role in drug treatment for one of several reasons, including the following:

When researchers compare the genomes of people taking the same drug, they may discover that a set of people who share a certain genetic variation also share a common treatment response, such as:

This kind of treatment information is currently used to improve the selection and dosage of drugs to treat a wide range of conditions, including cardiovascular disease, lung disease, HIV infection, cancer, arthritis, high cholesterol and depression.

In cancer treatments, there are two genomes that may influence prescribing decisions the genome of the person with cancer and the genome of the cancerous (malignant) tumor.

There are many causes of cancer, but most cancers are associated with damaged DNA that allows cells to grow unchecked. The "incorrect" genetic material of the unchecked growth the malignant tumor is really a separate genome that may provide clues for treatment. For example, the drug trastuzumab (Herceptin) is most likely to be effective against breast cancer cells that have an extra copy of a particular gene and high levels of the gene's corresponding protein.

.

Read the original post:
Personalized medicine and pharmacogenomics - Mayo Clinic

Related Posts

Comments are closed.